Categories
Tags
Abbott Advertising AstraZeneca Barack Obama Biotechnology and Pharmaceuticals Breast cancer Bristol Myers Squibb business Cancer Clinical trial Conditions and Diseases Deal Eli Lilly European Commission European Union FDA Food and Drug Administration Genentech generics GlaxoSmithKline Google GSK HBA Health Health care Johnson & Johnson layoffs Lilly Margaret Hamburg Marketing Merck Novartis Pfizer Pharma Pharmaceutical drug pharmaceutical industry Research and development Roche Sanofi-Aventis Schering Plough social media Twitter U.S. Food and Drug Administration United States Wyeth
Technology News
BioPharm News- Shire Gains European Approval for its Gaucher Disease Treatment
- Mtech Bioprocess Scale-Up Facility to Double in Staff and Size
- ImClone Closes Plant in New Jersey, Consolidating Erbitux Manufacture
- EMA and FDA Seek Applicants for Joint GMP Inspections
- ATMI Expands Bloomington, Minnesota Manufacturing Facility
Clinical Trials News- CRF Health Achieves EXACT ePRO Vendor Certification for Windows Mobile Systems
- ACR Image Metrix Establishes Global Presence
- BioPharm Systems Named to the 2010 Inc. 500|5000 List of Fastest-Growing Companies in the U.S.
- CRF Health Doubles North American Headquarters
- Oracle Completes Acquisition of Phase Forward
Blogroll
-
Meta
Category Archives: Emerging Markets
TB Alliance Trumpets New, Improved Drugs at World Health Assembly
Like polio and leprosy, developed countries have long since tamed tuberculosis. But even now, other parts of the world continue to struggle against the disease, with nearly all (98 percent) of TB’s 1.7 million worldwide deaths occurring in developing countries. TB’s high comorbidity with HIV infections has recently added another level of urgency to efforts [...]
Also posted in Corporate Responsibility, Global, R&D Tagged AIDS, Developing country, funding, HIV, Médicins Sans Frontières, neglected diseases, TB, TB Alliance, Tuberculosis, WHA, World Health Assembly Leave a comment
US and Europe At Risk from Substandard Medicines
Guest blog by Helen Disney, Chief Executive and Founder of the Stockholm Network, a pan-European think tank.
When most of us look at taking a new medicine we tend to think it will make us better. Some of us may think about possible side effects but few of us expect the medicines we take to actually [...]
Also posted in Biotech, Europe, Global, Guest Blog, Regulatory, Safety Tagged biosimilars, Brazil, China, counterfeit medicines, developing nations, Emerging Markets, Europe, Indian, Regulatory, substandard medicines, Turkey, US Leave a comment
Witty Proposes Price Cap for Poor Nations
GlaxoSmithKline CEO Andrew Witty proposed Friday to slash drug prices in the world’s 50 poorest countries and reinvest 20 percent of the profits in bolstering local health care. In a speech at Harvard Medical School Friday, Witty said drug prices will be capped at 25 percent of what they cost in developed nations. He also [...]
Also posted in Corporate Responsibility, People Tagged Andrew Witty, asthma, GSK, malaria Leave a comment
Gilead Making a Bundle
Gilead Sciences has once again proven that independent biotechs can innovate with the best of Big Pharma. The Silicon Valley company’s wizardry at weaving multiple drugs into a single weft enabled it to overthrow GlaxoSmithKline as king of HIV in 2007. Yesterday, at the 16th annual Congress of Retroviruses and Opportunistic Infections (CROI), the biotech [...]

GSK Scores High in Market Access